Center Laboratories, Inc.

TPEX:4123 Stock Report

Market Cap: NT$30.5b

Center Laboratories Past Earnings Performance

Past criteria checks 0/6

Center Laboratories's earnings have been declining at an average annual rate of -52.8%, while the Pharmaceuticals industry saw earnings growing at 8.2% annually. Revenues have been declining at an average rate of 5.9% per year.

Key information

-52.8%

Earnings growth rate

-52.9%

EPS growth rate

Pharmaceuticals Industry Growth18.5%
Revenue growth rate-5.9%
Return on equity-2.2%
Net Margin-26.4%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

We're Not Counting On Center Laboratories (GTSM:4123) To Sustain Its Statutory Profitability

Nov 20
We're Not Counting On Center Laboratories (GTSM:4123) To Sustain Its Statutory Profitability

Revenue & Expenses Breakdown

How Center Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

TPEX:4123 Revenue, expenses and earnings (TWD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,575-41544675
30 Jun 241,524-1,66743684
31 Mar 241,422-2,52844985
31 Dec 231,394-99545783
30 Sep 231,227-90341572
30 Jun 231,058-1,01838059
31 Mar 23951-26532655
31 Dec 2276810228847
30 Sep 22650-623764
30 Jun 22566-342-15468
31 Mar 224941,057-3072
31 Dec 215001,81629175
30 Sep 215513,89868276
30 Jun 215945,6591,11296
31 Mar 215675,695977103
31 Dec 207173,786693129
30 Sep 209242,275657174
30 Jun 201,1391,357452177
31 Mar 201,386138508208
31 Dec 191,438-286503206
30 Sep 193,6913,7691,529208
30 Jun 199,3565,3213,856372
31 Mar 1916,1185,4236,197625
31 Dec 1821,6486,0848,320732
30 Sep 1824,9002,4079,391955
30 Jun 1823,9508768,703939
31 Mar 1821,4757187,715820
31 Dec 1719,3922506,757806
30 Sep 1718,016-646,232735
30 Jun 1716,477905,657669
31 Mar 1715,588585,473575
31 Dec 1615,040195,305518
30 Sep 1614,5417034,943328
30 Jun 1613,2694904,521243
31 Mar 169,8044373,351172
31 Dec 156,7924222,335124
30 Sep 153,0261351,077123
30 Jun 151,00822374123
31 Mar 15944241315141
31 Dec 14899333282148
30 Sep 1488340225147
30 Jun 14824216211148
31 Mar 1477573193138

Quality Earnings: 4123 is currently unprofitable.

Growing Profit Margin: 4123 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 4123 is unprofitable, and losses have increased over the past 5 years at a rate of 52.8% per year.

Accelerating Growth: Unable to compare 4123's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 4123 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (11.9%).

Return on Equity

High ROE: 4123 has a negative Return on Equity (-2.22%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 07:40
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Center Laboratories, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yenya KuoCapital Securities Corporation
Regina LeeIBTS Investment Consulting Co., Ltd.
Li-chun ChangJih Sun Securities Investment Consulting Co., Ltd.